April 28 (Reuters) - MGC Pharmaceuticals Ltd MXC.AX :* MGC PHARMACEUTICALS - APPLICATION TO HEALTH CANADA FOR ARTEMIC APPROVAL
April 22 (Reuters) - MGC Pharmaceuticals Ltd MXC.AX :* MGC PHARMA TO ACQUIRE MEDICAL RESEARCH COMPANY MEDICANL* CONSIDERATION FOR ACQUISITION IS $6 MILLION IN MXC SHARES*...
March 23 (Reuters) - MGC Pharmaceuticals Ltd MXC.AX :* ETHICS COMMITTEE APPROVAL GRANTED PHASE III CLINICAL TRIAL-MXC.AX* RECEIVED ETHICS COMMITTEE APPROVALS FROM RAMBAM HEALTH...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Sell | Buy | Strong Buy |
| Technical Indicators | Sell | Strong Sell | Strong Sell | Strong Buy | Strong Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 0.525 | 0.00 | 0.00 | +0.045 | +9.38% | 11.88M | Sydney | |||
| 0.11 | 0.00 | 0.00 | 0.000 | 0.00% | 0.00 | Sydney | |||
| 15.17 | 15.21 | 14.50 | +0.550 | +3.76% | 4.80M | Sydney | |||
| 17.93 | 18.02 | 17.53 | -0.03 | -0.17% | 2.27M | Sydney | |||
| 5.53 | 5.56 | 5.45 | +0.08 | +1.47% | 12.99M | Sydney | |||
| 0.086 | 0.00 | 0.00 | -0.001 | -1.15% | 498.29K | Sydney | |||
| 14.18 | 14.215 | 14.04 | +0.130 | +0.93% | 8.20M | Sydney | |||
| 0.076 | 0.00 | 0.00 | -0.001 | -1.30% | 124.96K | Sydney | |||
| 0.895 | 0.00 | 0.00 | 0.000 | 0.00% | 0.00 | Sydney | |||
| 0.93 | 0.00 | 0.00 | 0.000 | 0.00% | 0.00 | Sydney | |||
| 6.07 | 6.19 | 6.00 | -0.090 | -1.46% | 23.59M | Sydney | |||
| 13.00 | 13.17 | 12.91 | 0.00 | 0.00% | 144.77K | Sydney | |||
| 0.29 | 0.00 | 0.00 | 0.000 | 0.00% | 0.00 | Sydney | |||
| 0.765 | 0.00 | 0.00 | -0.040 | -4.97% | 11.28M | Sydney | |||
| 1.83 | 1.86 | 1.79 | +0.01 | +0.83% | 15.18M | Sydney |
MGC Pharmaceuticals Limited is an Australia-based biopharma company. The Company is primarily focused on producing standardized, phytocannabinoid and plant-derived medicines. The Company’s Nature to Medicine strategy comprises the entire supply chain, from botanical research, to develop new strains of Cannabis Sativa, preclinical and clinical research, product manufacturing, distribution, as well as the development of drug delivery systems. The Group has also completed a Phase II double-blind, randomized, placebo controlled clinical trial in Israel and India, to evaluate the safety and efficacy of a natural anti-inflammatory based formulation ArtemiC on patients diagnosed with Corona Virus Disease 2019 (COVID-19).